Last reviewed · How we verify

Madopar monotherapy — Competitive Intelligence Brief

Madopar monotherapy (Madopar monotherapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine precursor / Decarboxylase inhibitor combination. Area: Neurology.

marketed Dopamine precursor / Decarboxylase inhibitor combination Dopamine pathway; aromatic L-amino acid decarboxylase (peripheral inhibition by benserazide) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Madopar monotherapy (Madopar monotherapy) — Peking University Third Hospital. Madopar combines levodopa and benserazide to increase dopamine levels in the brain by delivering levodopa across the blood-brain barrier while benserazide blocks its peripheral conversion.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Madopar monotherapy TARGET Madopar monotherapy Peking University Third Hospital marketed Dopamine precursor / Decarboxylase inhibitor combination Dopamine pathway; aromatic L-amino acid decarboxylase (peripheral inhibition by benserazide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine precursor / Decarboxylase inhibitor combination class)

  1. Peking University Third Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Madopar monotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/madopar-monotherapy. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: